Skip to content

Efficacy of Physiotherapy on the Health and Quality of Life of the Rheumatic Patient

Phase II Study of Physiotherapy in Rheumatoid Arthritis: Randomized Single Blind Wait-list Controlled Trial

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02020668
Enrollment
82
Registered
2013-12-25
Start date
2014-05-31
Completion date
2014-12-31
Last updated
2014-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatic Arthritis

Keywords

Pain, Functional capacity, Quality of Life

Brief summary

Despite leading cause of morbidity, treatment strategies for Rheumatic diseases are geared almost exclusively toward medical-pharmacological area away from offering the patient the possibility of an interdisciplinary approach to their disease. Present study test whether treatment of physiotherapy reduces stiffness and pain inherent in rheumatic disease and improve their quality of life related to health.

Interventions

OTHERPhysiotherapy

Sponsors

NMP Medical Research Institute
CollaboratorOTHER
Warwick Research Services
CollaboratorOTHER
Macmillan Research Group UK
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Patients older than 18 years * History of Rheumatoid Arthritis (RA) symptoms for less than 7 years * Had RA by American College of Rheumatology (ACR) criteria * ACR functional RA class I, II or III * Hemoglobin more than 8g/dL without evidence of active bleeding * Positive for rheumatoid factor (RF) or anti cyclic citrullinated protein * standard conventional medicine were allowed within the approved dosage regimen

Exclusion criteria

* connective tissue disease * any other alternative or complementary medicine with in last 3 months. * corticosteroid, disease modifying medicines * Poorly controlled diabetes, hypertension, hepatitis, cardiac disease, liver diseases, carcinoma, drug abuse

Design outcomes

Primary

MeasureTime frame
PainChange from baseline in Numerical Scale Downie at 16 weeks

Secondary

MeasureTime frame
Quality of LifeChange from Baseline in Short Form (SF) 36 at 16 weeks

Other

MeasureTime frame
Functional capacityChange from baseline in Barthel Index at 16 weeks

Countries

India

Contacts

Primary ContactVirendra Shekhawat, MA
shekhawatvans21@gmail.com+91-8824260512

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026